Biotech Incyte News

Incyte With Second Positive Pivotal Trial in Atopic Dermatitis (Eczema)

Biotech News | 19.02.2020

Incyte today announced that also the second of two identical phase 3 trials with Ruxolitinib cream...

Biotech Incyte News

Incyte With Second Positive Phase 3 Trial in Atopic Dermatitis Within Two Days

Biotech News | 28.01.2020

These are truly exciting days for Incyte. The American biopharmaceutical company and member of our...

Biotech Eli Lilly Incyte News

Eli Lilly and Incyte’s Olumiant Clears Pivotal Trial in Atopic Dermatitis

Biotech News | 27.01.2020

Incyte and Eli Lilly today announced the results from a phase 3 clinical trial with Olumiant...

Biotech Incyte News

Incyte Opts for Switzerland as its New European Headquarters

Biotech News | 10.11.2019

The American biotech company Incyte has chosen the Swiss city Morges as its European headquarters....

Biotech Incyte News

Incyte’s Ruxolitinib Cream with Positive Phase 2 Trial in Vitiligo

Biotech News | 14.10.2019

A phase 2 clinical trial with Incyte’s Ruxolitinib cream in patients with vitiligo met its...

Biotech Incyte News

Incyte with Positive Results from Phase 2 Trial of Pemigatinib in Advanced Cholangiocarcinoma

Biotech News | 27.09.2019

The US pharmaceutical company Incyte, a member of our Biotech Investments Model Portfolio which is...

Biotech Incyte News

Incyte Announces Successful Initiation of Phase 3 Program with Ruxolitinib Cream for Patients with Vitiligo

Biotech News | 25.09.2019

The US pharmaceutical company Incyte today released an announcement saying that the phase 3...

Biotech Incyte News

Model Portfolio Member Incyte Increases Turnover in the Second Quarter, Share Price Rises 6%

Biotech News | 30.07.2019

Our sample portfolio value Incyte today presented its annual report for the second quarter of 2019...